Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company opera... Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. 더 보기
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical...
Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 1.81818181818 | 1.1 | 1.39 | 1.06 | 175970 | 1.18200555 | CS |
4 | -2.13 | -65.5384615385 | 3.25 | 4.8 | 1.06 | 1223407 | 2.03533303 | CS |
12 | -0.22 | -16.4179104478 | 1.34 | 7.4899 | 0.46 | 2593744 | 2.61824372 | CS |
26 | -2.48 | -68.8888888889 | 3.6 | 7.4899 | 0.46 | 1141916 | 2.61442791 | CS |
52 | -0.53 | -32.1212121212 | 1.65 | 17.49 | 0.46 | 1185822 | 5.59613597 | CS |
156 | -16.78 | -93.7430167598 | 17.9 | 23.3 | 0.46 | 470899 | 6.10508959 | CS |
260 | -146.28 | -99.2401628223 | 147.4 | 182.5 | 0.46 | 597792 | 17.6717086 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관